The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
ivans ..
Yes, I think it's a very good market to be in at the mo...seems to be going in that direction, but with politics , who knows long term
By the way, for investors, there's a small technical gap to be filled just under 3p, which maybe get a sniff tomorrow morning..It's a possibility but not a cert, as gaps sometims don't get filled (usually do)
Well , Herts..
Thanks for getting back to NFX..
I did try (not very hard) ...but my first question (never answered - only in slag-offs) was, what is this Ā£51M all about?
My feeling is that they've played a canny PR game, with Ā£1M up front, so waht, keeps it ticking over.
If the tech is positive (come end May/early June) then this could really take off. There's been a seller (Spreadex? In background for ages). Is Juilan Higgins a pro trader or invester (he can be found on the internet in other companies for those who want to read)
I would think this is definitely going to reside between 3p and 4p , maybe more if seller clears, after this RNS. Before this , I would have said that 4p was optimistic , but maybe there's other 'curveballs' as they say ;o)
so, after this RNS, I'm of the ilk of, WTFDIK...As it stood it seemed pretty pedestrian, but now..well..sounding more sexy!
There was a heavy hint of PR about this RNS, but with the tech, it could be a giant in the making, or the fag end of a 1965 spliff
On too little volume..back down to 2.4p boys!
Compared to most people on here Iām also a bit sceptical of how far this is going up if successful results are accomplished.
Sure , thereāll be a lift, but this idea that the market doesnāt understand NFX and that itās āhiddenā somehow.
What if the Market is already valuing in what it expects to be very good test results?
I still canāt see much more than 4p to 6p on even great results. Slow burner this one - and future funding will need some good licensing/ royalties from NFx001 to fend-off dilution.
I still donāt see anywhere past 6p in the next 12 months, even with terrific results from this trial. Danās hoping for a 5-year business sell-off model. A lot can happen in 5 years. Anyone with any experience of small MC companies will know that if this gets good results and spikes, to de-risk a few, and get a free-ish ride.
Jay, I thought youād ātopped up ā enough already?!
Some good posts...enjoyed reading everyone.
Aim, just a couple of comments about statements like āthis should never have been under 3pā...and āThis wonāt fail!ā
I agree with Jay (and probably a few more) that this should not have been floated circa Ā£18M and that was on the high side, especially with lengthy timeframes (already the company has been going over 10 years)..
But Market valuation is an unruly beast, based on a mixture of prospects, potential, expertise, time frames and those intangibles such as āsexinessā of product and sentiment.
Personally, I think this has been very well valued over the last year or so..It hasnāt proven any human prospects as of yet, has had a few small delays, is certainly not āsexyā (yet!), and sentiment is hard to maintain on potential alone.
Weāve certainly got the expertise, weāve got the potential...but the next few months will see whether it does actually deliver..
So....getting on to the phrase āIt canāt failā..
Well, it certainly can āfailā..
Failure will be if it doesnāt reach a certain relativity of success compared to the parent drug. So, I agree, that absolute failure is low risk - notwithstanding the possibility that a massive boost in patient absorption may cause as of yet unknown detrimental effects ..
But, failure can occur by the product not reaching the multiple absorption effect that the Market expects, and therefore other potential products are killed-off. And the Market, as Aim stated, expects us to get to 80% maybe..
So, letās say we achieve 10 to 50% extra absorption, will this lead Mr Market to believe that licenses , based on future sales, will be signed? Will it believe that extra drug costs to patients and health bodies are worth the relatively minimal (compared to expected) absorption and longevity. Will drug companies then want this over existing drugs? Will the cost/patient experience profile endorse that?
Thatās failure :
That the Market expects a certain efficacy and success, and trials donāt come up to expectation.
Thatās why there is risk, and thatās why weāre at where weāre at.
..although with Monday being ISA year, wonder if there may be a few who've been waiting to buy until Monday..
we'll see (although you can't buy many at the moment - unless MMs have a few stockpiled to let go)
Low volume rise this one, doesn't have credibility with trial results 8 weeks away. That's moe than a week in politics.
It could be the MMs re-rating up to 3p+, or fishing for a few more shares (no-one's biting), but think this will be back to 2.5p before it gets to 4p.
Happy to be proved wrong, and I'm sure many many many of you on here will have another view!
a) depends if it is his "own" cash and not representative
b) Depends how much money he's got in total, and may be out for a fast large buck on the rise and spike
c) It may be anyone/someone in the business who knows the company's workings and is LTH for the full ride.
d) It could be someone/anyone - like on this board - or elsewhere who's got a lot of cash and been (over-enthusiastically) building overtime
e) It could be a rich trader, who does this a lot with other companies for quick profit - be interesting to see if he's been a bigwig in other shares
That with new tax year starting next Monday that some may be selling a few to buy back in ISA.
thereās always a few sells before April 6 - and short term technicals may be tempting people to gamble a little that by next week buy-back may be lower than at the moment,
Totally missed that 20 -day Moving Average was crossed for this upturn...doh
Big boom time usually co,mes when 50 and 200 cross...and they are moving to converge in next few weeks - which ācoincides ā with news time
Very low volume - major candlestick reversal pattern āhanging manā today - so, end of the little upturn IMO, probs slip back.
Donāt take my word - wait for tomorrow. No volume, so no ramping/deramping, itās being pushed minimimally by MMs at the mo...hoping people would bite today - not-one;ās taking it.
ps...there's probably between 0 and 1% chance this will have a Market Cap of Ā£50Million after trial results.
Softly softly catchee monkey. Although some of you monkeys appear to be one level beneath genetically.
Just had a look..
Nothingās changed my mind about where this is going - upwards - but more slowly than peeps think on here.
Nfxoo1 , I believe , if tests are good, will give us a re-rate, but not astronomically, and attendant licensing deals will keep the pot boiling.
Dan has now stated on the record that Nfx002 absorption results (and vitally taking that forward in humans) will not be under 12 months from now - so realistically, until then, I think this will bobble around somewhere in the region of 4p to 6p (Market Cap up to Ā£30Mill - even that might be rather ambitious at this stage).
Any of the crew on here who thinks Iām āderampingā whatever that mean (ie since Iām predicting a share price rise!), will only have Old Father Time to attest that this is or isnāt the case.
I suppose it also depends on the type of licensing deals and the additional possibly benefits of NFx001 that may add value, but, again, there seems to be a rather large gap between the NFx001 results and starting Nfx002 trials. And that time needs to be filled with news - or share dribble again.
I would think my best mate Aim will have sold most of his by then on a spike.
Hi Inner - yes, all good Ooooooop north.
Just eaten a couple of Aim-types for breakfast (a bit insipid, with a nasty aftertaste) before walking the whippet, and taking the local pigeon down tālocal tāshops.
About to put a ferret down me troozers for normal Satāday afternoon thrill.
You asked about MC if trials are successful. Well, the only thing I can refer to with any empirical evidence of late is one of Jivingās posts from a few months ago, where the company (canāt remember the name) - Jiving? Had a $300M deal pocketed but was still floating around $60M market Cap.
Itās going to depend on deals and future revenue, but I think it will take a while to get where we want to it. Post trials if successful, weāll obviously have a sharp increase...to where? Well, Iām guessing that it may get us to around the 4 to 6p mark, then itāll be a re-rate to that level.
But steady revenues tend to bring a steady rate of climb rather sharp massive climbs, so I think itāll then (depending on future licences) be a matter of softly softly, with incremental rises attendant to the deals.
My personal view that if it all goes well over the next year, weāll be somewhere around the 6 - 10p mark, but then thereās the other product line to come into focus...so could be very exciting, an think thereāll be a LOT of movement behind the scenes references licences if these trial go well.
What do you reckon?
All the best, PC
Explain what? Trial results not due for 8 weeks.
Poster Investor1111 or whatever his name - blasted as a deramper for sating share price always goes down to 2p days after news.
Anyway, thatās it with you.
I wont filer you because other comments from others may be relevant, but thatās the last post I read or respond to from you.
youāre toxic.
And 5th point to Jay.
You say thereās 20% free float so itās better to get sticky hands on it.
Incorrect IMO - the small free float and lack of liquidity means we will want a quick turnover rise with less sticky hands.
Aim.. First , Iād like to ask a direct question and would appreciate a direct answer, not a general attack which Iām sadly expecting
A few days ago, you told a poster that āSpreadex were not sellingā.
How do you know that?
2nd point: I see thereās been some mob attack of a poster today who dared to say this will fall back to 2p..it may not, but I think itās entirely possible,
News is not due until towards the end of May, even end of June. Nothing has changed with that - so we have 6 to 8 weeks at least for the price to be beholden to the seller (Spreadex I believe)
3rd Point: To Jay..Leviritt, or other, aren;t āselling into the riseā Look at the prices. They are simply selling, as these institutions, hedge funds, investment bodies etc always have, always will , to free-up cash - even at a loss. Risk management etc.
I believe itās Spreadex - but I have no evidence - it just makes sense and we have a prior RNS to this effect.
Thatās why Iād like Aim to explain his comment please.
4th point: Just a quickie of your mateās Million buy Jay: It looks like it may have been the two 500K trades put through separately maybe?
In whichever case, no-one really outside this is insular group of posters and mates is buying - and the occasional ramping crew. We do have a continuous seller, but external buyers are still unconvinced. It seems apparent (obvious even) that other licensees are waiting for NFx001 results before signing up to this)
The trial results by the end of H1 (June) will be EVERYTHING. Everything else is just noise, and no share price rise will stick until then IMO.